Article Correctness Is Author's Responsibility: Potential Targeted Treatment for Acute Myeloid Leukemia Identified

Newswise imageScientists from Sanford Burnham Prebys have shown that a protein called BMI1 is a promising drug target for an AML subtype in which two normally separate genes, CALM and AF10, fuse together. The findings, published in Experimental Hematology, provide a rationale for evaluating a BMl1-inhibiting drug that is currently in clinical development for solid tumors.